A Review of the Impact of Sjögren’s Syndrome and/or the Presence of Anti-Ro/SS-A Antibodies on Therapeutic Strategies for Rheumatoid Arthritis

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(2), P. 568 - 568

Published: Jan. 17, 2025

Rheumatoid arthritis (RA) is an immune-mediated disease characterized by polyarthritis that affects the small joints of bilateral upper and lower extremities. RA shares several common clinical symptoms with Sjögren’s syndrome (SS), another rheumatic caused lymphocytic infiltration exocrine glands, dry eye mouth being two most symptoms. Anti-Ro/SS-A antibodies, a diagnostic biomarker SS, are positive in patients at certain rate. The coexistence SS and/or positivity for anti-Ro/SS-A antibodies influences activity effectiveness classes disease-modifying antirheumatic drugs (DMARDs). Furthermore, RA, DMARDs, including methotrexate, associated onset lymphoproliferative disorders (LPD). In contrast, biological such as tocilizumab rituximab, plausible options without risk LPD relapse. Considering results studies introduced this article, could be considered phenotype different from isolated perspective refractoriness to DMARD therapy risk. Hence, rheumatologists should observe caution when choosing DMARDs. Further needed establish appropriate treatment presence antibodies.

Language: Английский

Recent Advances in Pathogenesis, Diagnostic Imaging, and Treatment of Sjögren’s Syndrome

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(22), P. 6688 - 6688

Published: Nov. 7, 2024

It is our pleasure to present the Special Issue "Diagnosis and Treatment of Sjögren's Syndrome" readers

Language: Английский